首页> 外文期刊>PLoS One >Trends in de-lousing of Norwegian farmed salmon from 2000–2019—Consumption of medicines, salmon louse resistance and non-medicinal control methods
【24h】

Trends in de-lousing of Norwegian farmed salmon from 2000–2019—Consumption of medicines, salmon louse resistance and non-medicinal control methods

机译:2000 - 2019年挪威养殖鲑鱼脱胶的趋势 - 鲑鱼冲突抗性和非药物控制方法

获取原文
           

摘要

The salmon louse Lepeophtheirus salmonis has been a substantial obstacle in Norwegian farming of Atlantic salmon for decades. With a limited selection of available medicines and frequent delousing treatments, resistance has emerged among salmon lice. Surveillance of salmon louse sensitivity has been in place since 2013, and consumption of medicines has been recorded since the early 80’s. The peak year for salmon lice treatments was 2015, when 5.7 times as many tonnes of salmonids were treated compared to harvested. In recent years, non-medicinal methods of delousing farmed fish have been introduced to the industry. By utilizing data on the annual consumption of medicines, annual frequency of medicinal and non-medicinal treatments, the aim of the current study was to describe the causative factors behind salmon lice sensitivity in the years 2000–2019, measured through toxicity tests–bioassays. The sensitivity data from 2000–2012 demonstrate the early emergence of resistance in salmon lice along the Norwegian coast. Reduced sensitivity towards azamethiphos, deltamethrin and emamectin benzoate was evident from 2009, 2009 and 2007, respectively. The annual variation in medicine consumption and frequency of medicinal treatments correlated well with the evolution in salmon louse sensitivity. The patterns are similar, with a relatively small response delay from the decline in the consumption of medicines in Norway (2016 and onward) to the decline in measured resistance among salmon louse (2017 and onward). 2017 was the first year in which non-medicinal treatments outnumbered medicinal delousing treatments as well as the peak year in numbers of cleanerfish deployed. This study highlights the significance of avoiding heavy reliance on a few substance groups to combat ectoparasites, this can be a potent catalyst for resistance evolution. Further, it demonstrates the importance of transparency in the global industry, which enables the industry to learn from poor choices in the past.
机译:鲑鱼Louse Lepeophtheorus Salmonis在大西洋鲑鱼的挪威养殖几十年来一直是一个重要的障碍。在有限选择可用的药物和频繁的漂白处理中,鲑鱼虱子中出现了抗性。自2013年以来,Salmon Louse敏感性的监测已经到位,自80年代初以来,药物的消费已被记录。鲑鱼虱子治疗的高峰年为2015年,与收获相比,当收获时处理了5007倍的鲑鱼。近年来,已经向行业引入了漂白养殖鱼类的非药用方法。通过利用关于药物的年消耗,药物和非药物治疗的年频率,目前研究的目的是描述通过毒性试验 - 生物测定的2000 - 2019年鲑鱼虱敏感性背后的致病因素。 2000 - 2012年的敏感性数据证明了挪威海岸鲑鱼虱子的早期出现。从2009年,2009年和2007年,分别从2009年,2009年和2007年显而易见的是对Azamethiphos,Deltamethrin和Emamectin Benzoate的敏感性。药物治疗的年度变化与药物治疗的频率与鲑鱼虱敏感性的进化相关。这些模式类似,具有相对小的反应延迟,从挪威(2016年和向内)的药物消耗的下降到鲑鱼虱(2017和向内)的测量抗性下降。 2017年是第一年的非药物治疗数量超过药物杂散治疗以及部署的清洁鱼数量的高峰年。本研究突出了避免对少数物质基团进行打击异醛酸盐的重要性的重要性,这可以是抗性进化的有效催化剂。此外,它展示了全球产业透明度的重要性,这使得该行业能够从过去的选择中学习。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号